News | January 10, 2008

Next Generation of Aspirin Absorbs through Mouth Lining

January 11, 2008 - The latest advancement in aspirin is “Fasprin,” an 81mg tablet that enters the bloodstream through the lining of the mouth after rapidly dissolving on the tongue, which recently launched by Improvita Health Products.

A Fasprin tablet quickly dissolves on the tongue in three to five minutes, enabling the aspirin to enter the blood stream faster than conventional aspirin, which breaks down in the stomach. Clinical trials are currently underway to compare the efficacy of Fasprin with that of enteric-coated aspirin and determine how quickly the dosage reaches the bloodstream.

The company said the ability for aspirin to rapidly enter the blood stream has far-reaching advantages for heart attack and stroke sufferers, whose best line of defense at the first sign of an attack is immediately taking aspirin. Aspirin has been proven to stop blood platelets from sticking together, which reduces the chance for blood clots to form and block arteries.

The low-dose aspirin can be used by people who are on an aspirin regimen as a preventative measure against heart attack and stroke. The company said it is ideal for people who have trouble swallowing conventional aspirin, or experience gastric irritation

For more information: www.improvita.com/Fasprin-news, www.Fasprin.com

Related Content

Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
Overlay Init